High-Risk CLL: Current Treatment Considerations with Novel Agents and HCT

This review examines currently available evidence and theoretical considerations to advise patients with high-risk chronic lymphocytic leukemia (CLL) about the indication and timing of HCT versus the administration of novel classes of drugs such as BCR-signal inhibitors and BCL2 antagonists. The authors propose that all patients with high-risk CLL be considered for treatment with these novel agents along with discussion of HCT options for those patients responding or not responding to them.

Dreger P, et al. Blood

Related Resource